• Health technology assessment (HTA) bodies require lifetime estimates of mean costs and outcomes for all relevant technologies.
Introduction
• Health technology assessment (HTA) bodies require lifetime estimates of mean costs and outcomes for all relevant technologies.
• Cost-effectiveness models often use time-to-event data to estimate these costs and outcomes.
• Pairwise meta-analysis and network meta-analysis (NMA) are commonly used to estimate relative treatment effects for time-to-event endpoints, which should be based on systematic reviews of the clinical literature. 1 • These analyses often use published hazard ratios (HR) as the measure of relative treatment effect, therefore assuming proportional hazards (PH).
o Guidance from the NICE Decision Support Unit (DSU) recognises the importance of using an appropriate scale when synthesising time-to-event data, and in particular the importance of validating the PH assumption. 2 o Application of HRs when the PH assumption is violated can lead to biased estimates of mean time-to-event and hence cost-effectiveness. 3 • Time ratios (TRs), which are estimated from accelerated failure time (AFT) models, are recommended as an alternative measure of relative treatment effect when the PH assumption is violated, provided the associated AFT assumption holds. 4, 5 o However, we believe TRs are not commonly utilised in evidence synthesis due to unfamiliarity around interpretation, which may have discouraged their use.
o In addition, TRs are rarely reported in clinical trial publications.
• Methods now exist to reconstruct individual patient data (IPD) from published Kaplan-Meier (KM) plots. 6 This enables;
o The PH assumption to be formally tested for all studies reporting KM plots using methods recommended by the NICE DSU. 5 o A TR to be estimated from an AFT model fitted to the IPD and the associated assumption to be formally tested.
Objectives
• To compare TRs with HRs to demonstrate their ease of interpretation and transparency in order to encourage analysts to consider their use in evidence synthesis for cost-effectiveness analyses.
Methods
• Relative treatment effect measures HRs and TRs were compared in terms of:
o Derivation
• How to derive the relative treatment effect from IPD and published survival data.
o Interpretation
• Effectiveness of treatment compared to control in terms of survival outcomes.
• Direction of the treatment effect: more effective, less effective or equivalent to the control.
o Scale
• How the relative effect of treatment is measured.
o Underlying assumptions and associated tests
• Assumptions made about the underlying survival data and the impact of a covariate such as treatment on the hazard or time-to-event.
• Tests to assess whether these assumptions hold for a given dataset.
o Availability in published literature
• Level of reporting of relative treatment effects for time-to-event endpoints in clinical trial publications.
• Implications for systematic review and evidence synthesis.
• A descriptive comparison of HRs and TRs is presented in Table 1 .
Results
Time ratios or hazard ratios: accelerating toward a new approach? • PH models:
The effect of one treatment is interpreted in terms of its effect on the hazard, relative to another treatment.
• The hazard h(t) represents the instantaneous event rate at a given time point (i.e. probability the event occurs in the next instant given that the patient is event-free).
• Assume two comparative treatment arms (treatment (T) and control (C)):
• The hazard at any time t for treatment is proportional to the hazard at the same time for control.
• Estimated from fitting an AFT model to IPD.
• AFT models:
o Gamma • The effect of one treatment is interpreted in terms of its effect on the time-to-event, relative to another treatment.
• Assume S T (t) is the survivor function for patients receiving treatment and S C (t) is the survivor function for patients receiving control:
o The time-to-event of a patient receiving treatment is a multiple of the time-toevent time of a patient receiving control, for any time t.
o The probability a given patient receiving treatment survives beyond time t is equal to the probability a given patient receiving control survives beyond t/TR.
• The HR represents the relative treatment effect.
• The TR represents the relative treatment effect.
• The acceleration factor (AF) is the inverse of the TR, hence is easily derived:
• HRs represent the ratio of hazards at a given time point for treatment vs. control.
• TRs represent the ratio of event times at a given survival probability for treatment vs. control.
• AFs are the inverse of TRs.
• Point estimates reported in clinical trial publications represent the average treatment effect over the follow-up. Interpretation
• HRs act on the baseline hazard scale (Box 1):
o HR < 1, the event hazard is smaller on treatment vs. control o HR = 1, the event hazard is equal on treatment vs. control o HR > 1, the event hazard is larger on treatment vs. control • An example of how to interpret a HR is provided in Box 1.
• TRs act on the baseline time scale (Box 1): • AF can be interpreted in terms of any percentile (p) of the survival distribution for two treatment groups (e.g. median)
• The p'th percentile of the survival time distribution for treatment is such that:
• This can be obtained from the survival curve for an AFT model as in Figure 1 .
• HRs are interpreted as the increase or decrease in hazard rate relative to the control.
• TRs are interpreted as the increase or decrease in time-to-event relative to the control.
• TRs can be calculated directly from point estimates of survival (e.g. medians).
• The direction of the treatment effect is equivalent for HRs and AFs.
Scale
• In PH models, the relative treatment effect is represented on the log-hazard scale.
• The difference in the log hazards between treatment arms represents the log HR.
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• Log HRs are assumed to be normally distributed.
• NMA of HRs can use the same model as for any continuous outcome (assumed to be normally distributed) whereby the difference in log HRs is synthesised across studies.
• In AFT models, the relative treatment effect is represented on the log-failure time scale, where the failure time is the time-to-event.
• The difference in the log failure times between treatment arms represents the log TR.
• Log TRs are assumed to be normally distributed.
• NMA of TRs can use the same model as for any continuous outcome (e.g. log HR) whereby the difference in log failure times is synthesised across studies.
• A HR is based on the log-hazard scale whereas a TR is based on the log-failure time scale
• The same NMA methodology can be used for HRs or TRs given both can be represented as continuous outcomes.
Underlying assumptions and associated tests
• PH models assume that the hazards are proportional between treatment arms over time.
• The relative treatment effect acts multiplicatively on the hazard (i.e. hazard rate x HR).
• This assumption can be tested by plotting the cumulative hazard against time (either on the natural or log scale) for both arms:
o Parallel lines indicate proportional hazards, validating HRs as an appropriate measure of relative treatment effect.
• This plot can be generated using standard software packages from reconstructed IPD.
• AFT models assume that the relative treatment effect acts multiplicatively on the time-to-event (i.e. time-to-event x TR) and this effect is constant over time.
• This assumption can be tested by plotting the survival time quantiles for treatment against those for control (quantile-quantile plot):
o i.e. plotting survival at times t q for equally spaced apart quartiles q.
o Straight lines indicate a multiplicative effect of treatment on time, validating TRs as an appropriate measure of relative treatment effect.
• Both measures make underlying assumptions about the survival data.
• These assumptions should be formally assessed where possible using appropriate tests.
• Where the original IPD are not available, these tests can be conducted using reconstructed datasets.
Availability in published literature
• HRs are commonly reported in clinical trial publications (full paper, conference abstracts/presentations) as the measure of relative treatment effect for time-to-event outcomes.
• This is due to the Cox model being the commonly used approach for estimating average treatment effects in clinical trials.
• TRs or AFs are rarely reported in the clinical literature as the measure of relative treatment effect for time-to-event outcomes.
• However o KM graphs are commonly reported in full publications.
o Summary statistics such as the median survival and alternative percentile survival times can be reported in both conference abstracts and full publications.
• Methods exist to reconstruct IPD from published KM graphs 6 (Box 2).
• Consequently, TRs can be derived based on published data.
• In pairwise meta-analysis/NMA, the relative treatment effects across studies are synthesised.
• These should be based on systematic reviews of the clinical literature.
• TRs are rarely reported in clinical trial publications, making these less accessible than HRs for evidence synthesis.
• Survival data is commonly presented graphically as a KM curve from which IPD can be re-constructed.
• Reconstructed IPD or summary survival data can be used to estimate TRs using AFT parametric survival models. • Algorithm developed in the statistical package R (code provided in appendix of publication).
• Maps from digitised published KM curves back to KM data in order to reconstruct the IPD.
• Utilises commonly published survival data (KM graph, numbers of events and numbers at risk) as inputs.
• The IPD can then be used for:
o Estimating a relative treatment that may not have been published.
o Formally testing modelling assumptions.
Discussion
• In contrast to HRs which act on the baseline hazard scale, TRs act on the baseline time-to-event scale such that the time-to-event of a patient on treatment is a multiple of that for a patient on control.
o When modelling disease progression, the treatment modifies the speed of disease progression relative to to control which has an intuitive appeal. 8 • TRs can be easily converted into AFs, which have a number of benefits in terms of their interpretation:
o Same direction of benefit as HRs.
o Can be obtained from any ratio of percentiles from the survival time distribution (e.g. ratio of median event times).
• AFT models, which estimate TRs, contain a broader range of more flexible parametric distributions compared to PH models o Their ability to handle non-monotonic hazard functions may render them more appropriate when applied to cancer datasets.
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• Despite relative treatment effects rarely being reported as TRs in the clinical literature, these can be estimated from published survival data;
o The algorithm published in Guyot (2012) provides a method for reconstructing IPD.
o AFT models can be fitted to the IPD to estimate relative treatment effects as TRs.
o In addition, a TR can be estimated directly from a KM graph, medians or any percentile of survival times without the use of algorithms. However, as this approach is not based on an AFT model fitted to the IPD, the TR estimated may differ by time point assessed.
Limitations
• To estimate a TR, the functional form of the AFT model (e.g. lognormal), and hence the baseline risk must be specified. The Cox model is semi-parametric and therefore does not require this to be specified.
• The use of algorithms to reconstruct IPD may introduce bias and uncertainty however the outputs can be validated against the published data.
• Some publications may not report a KM graph, in which case the algorithm described in Guyot (2012) cannot be used.
• Where the PH assumption does no hold for a given dataset, this does not automatically imply that the AFT assumption will hold.
Conclusions
• TRs are alternative measure of relative treatment effect that can be considered in cases where the PH assumption does not hold, provided the AFT assumption is satisfied.
• Application of HRs when the PH assumption is violated can lead to biased estimates of mean time-to-event and hence cost-effectiveness.
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• Although not commonly reported in clinical trial publications, TRs can be estimated from KM plots or summary survival data.
• Therefore, evidence synthesis conducted for cost-effectiveness analysis should no longer rely on published HRs as the measure of relative treatment effect when the PH assumption is violated.
